Lecba Zdraví trávicího systému
Prozkoumejte dostupnou lecbu zdraví trávicího systému. Vse zahrnuje posouzeni nezavislym lekarem z EU, originalni leky z licencovanych lekaren a diskretni expresni doruceni.
Zdraví trávicího systému
Hyoscine Butylbromide (OTC)
Hyoscine butylbromide is an antispasmodic medication that relieves abdominal cramps and spasms. Particularly effective for irritable bowel syndrome (IBS), menstrual cramps, and other smooth muscle spasms in the gastrointestinal tract.
Lubiprostone (Amitiza)
Lubiprostone is a prescription medication for chronic constipation and irritable bowel syndrome with constipation (IBS-C). It works by increasing fluid secretion in the intestines to soften stool and promote bowel movements.
Omeprazole (OTC low-dose / Prescription high-dose)
Omeprazole is a proton pump inhibitor (PPI) that reduces stomach acid production. Effective for treating acid reflux, GERD, stomach ulcers, and other acid-related conditions. Low doses are available OTC, while higher doses require prescription.
Rifaximin (Xifaxanta)
Rifaximin is a non-absorbed antibiotic used to treat irritable bowel syndrome with diarrhea (IBS-D) and traveler's diarrhea. Because it stays in the gut, it has fewer systemic side effects than traditional antibiotics.
Semaglutide (Ozempic)
Semaglutide (brand name Ozempic) is a GLP-1 receptor agonist used for weight management and type 2 diabetes. It mimics the GLP-1 hormone to reduce appetite, slow digestion, and improve blood sugar control. Administered as a once-weekly injection.
Simethicone (OTC)
Simethicone is an anti-foaming agent that helps relieve gas, bloating, and pressure caused by excess gas in the digestive tract. Safe for most people including children and pregnant women.
Interested in Zdraví trávicího systému?
Complete a confidential health assessment reviewed by an independent EU-registered doctor.
Start AssessmentDigestive health léčba v Evropě
Gastrointestinal conditions affect a substantial proportion of the European population and account for a significant share of primary care consultations. Among the most prevalent are gastro-oesophageal reflux disease (GORD), peptic ulcer disease, and related acid-mediated conditions. It is estimated that GORD affects approximately 10–30% of the Western adult population, with heartburn and acid regurgitation being among the most commonly reported symptoms in primary care.
GORD occurs when stomach acid flows back into the oesophagus, causing inflammation, discomfort, and — in persistent cases — structural changes such as erosive oesophagitis or Barrett’s oesophagus. Risk factors include obesity, smoking, dietary factors, certain medications (particularly NSAIDs), and conditions that increase intra-abdominal pressure such as pregnancy.
Peptic ulcers — ulcerations in the stomach or duodenum — are most commonly caused by infection with Helicobacter pylori bacteria or long-term NSAID use. Management typically involves a combination of acid suppression and, where H. pylori is confirmed, antibiotic eradication therapy.
The mainstay of pharmacological treatment for acid-related digestive conditions is the proton pump inhibitor (PPI) class, which includes omeprazole, lansoprazole, pantoprazole, and esomeprazole. PPIs provide potent and sustained acid suppression and are among the most widely prescribed medications in Europe. H2 receptor antagonists such as famotidine offer an alternative mechanism of acid reduction and remain in clinical use.
All treatment decisions must be made by a qualified, independent doctor based on thorough assessment of symptoms, duration, and relevant clinical history.
Dostupné léčby
The following medications may be available for digestive health conditions through EU-registered doctors. This comparison is provided for informational purposes only.
| Medication | Active Ingredient | Class | Primary Indication |
|---|---|---|---|
| Omeprazole | Omeprazole | Proton pump inhibitor (PPI) | GORD, peptic ulcer, H. pylori eradication |
| Lansoprazole | Lansoprazole | Proton pump inhibitor (PPI) | GORD, peptic ulcer, H. pylori eradication |
| Famotidine | Famotidine | H2 receptor antagonist | GORD, peptic ulcer, heartburn |
Key distinctions:
- Omeprazole: The original PPI and a widely used reference standard. Generic formulations are broadly available and cost-effective. Effective for most acid-related conditions.
- Lansoprazole: A PPI with comparable efficacy to omeprazole. Some patients may experience improved tolerability or response with one PPI over another. Available in standard and orodispersible formulations.
- Famotidine: An H2 blocker with faster onset than PPIs (useful for on-demand use) but less sustained acid suppression. Suitable for milder symptoms or as an adjunct to PPI therapy in some cases.
Note on ranitidine: Ranitidine was withdrawn from EU markets in April 2020 following regulatory action by the EMA due to NDMA contamination concerns. It is no longer available in EU member states.
Jak získat léčba online
Prescrivia působí jako technologický zprostředkovatel: nepředepisujeme léky, nezaměstnáváme lékaře ani neprodáváme léky. Naše platforma spojuje pacienty s nezávislými lékaři registrovanými v EU, kteří mohou provádět důvěrná online zdravotní posouzení.
Postup je následující:
-
Vyplňte zdravotní dotazník — Answer a structured set of medical questions covering your symptoms, their duration and frequency, dietary and lifestyle factors, current medications (particularly NSAIDs), and any previous investigations such as endoscopy or H. pylori testing.
-
Independent doctor review — An independent EU-registered doctor reviews your assessment. If a prescription digestive medication is clinically appropriate, the doctor may issue a prescription. If symptoms suggest the need for urgent investigation, the doctor will advise accordingly.
-
Předpis a vyřízení — If a prescription is issued, it is passed to a licensed EU pharmacy partner. The pharmacy dispenses the medication and arranges delivery to your address.
Důležité: Prescrivia nezaručuje, že bude předpis vystaven. Veškerá rozhodnutí o předepisování provádějí nezávisle kvalifikovaní odborní lékaři na základě Vašich individuálních klinických okolností.
Jak se srovnáváme
| Prostřednictvím Prescrivia | Osobní návštěva u lékaře | |
|---|---|---|
| Dostupnost | 24/7 online assessment | Subject to appointment availability |
| Čekací doba | Assessment reviewed within hours | Days to weeks depending on location |
| Cestování nutné | No | Yes |
| Rozhodnutí o předpisu | Made by independent EU-registered doctor | Made by your GP |
| Ongoing monitoring | Supported via follow-up assessments | Managed by your GP |
| Náklady | Transparent pricing displayed upfront | Varies by country and healthcare system |
Note: Digestive symptoms that may indicate serious underlying pathology — including difficulty swallowing, unexplained weight loss, blood in stools, or new-onset symptoms in adults over 55 — require urgent in-person evaluation. Prescrivia’s platform is designed for adults with established, uncomplicated acid-related digestive conditions suitable for remote assessment.
Zdroje
Lékařské informace na této stránce vycházejí z následujících zdrojů:
- European Medicines Agency (EMA). Omeprazole — Summary of Product Characteristics. Available at: ema.europa.eu
- Vakil N, et al. The Montreal definition and classification of gastroesophageal reflux disease. American Journal of Gastroenterology. 2006.
- World Health Organization (WHO). Gastrointestinal diseases — WHO data and statistics. who.int
Tento obsah je pravidelně přezkoumáván s ohledem na aktualizované klinické pokyny. Je poskytován pouze pro informační účely a nepředstavuje lékařské poradenství. Vždy se poraďte s kvalifikovaným zdravotnickým pracovníkem o radě týkající se Vašich individuálních zdravotních okolností.
Frequently asked questions
- Mohu získat Zdraví trávicího systému online v Evropě?
- Přístup k přípravku můžete získat prostřednictvím online zprostředkovatelských platforem, které Vás spojí s nezávislými lékaři registrovanými v EU. Po vyplnění důvěrného zdravotního dotazníku lékař posoudí, zda je lék pro Vás klinicky vhodný.
- Jaký je rozdíl between omeprazole and lansoprazole?
- Both are proton pump inhibitors (PPIs) that reduce stomach acid production by blocking the proton pump in gastric parietal cells. They have similar efficacy profiles for most indications. The choice between them depends on clinical factors, drug interactions, and individual patient response, which the reviewing doctor will assess.
- Is ranitidine still available in Europe?
- Ranitidine (an H2 receptor antagonist) was withdrawn from EU markets in 2020 following the discovery of unacceptable levels of NDMA (a probable carcinogen) in some formulations. Alternative H2 blockers such as famotidine remain available. A doctor can advise on the most appropriate current treatment options.
- Jak dlouho can I take a proton pump inhibitor (PPI)?
- PPIs are highly effective for acute conditions and are often prescribed for 4–8 weeks for conditions such as peptic ulcers. Long-term or indefinite PPI use may be appropriate for conditions such as chronic GORD or Barrett's oesophagus, but carries risks including magnesium deficiency, Clostridium difficile infection, and potential reduced bone density. Long-term use should be reviewed regularly by a doctor.
- What digestive symptoms require urgent in-person assessment rather than online treatment?
- Symptoms including unexplained weight loss, difficulty swallowing (dysphagia), vomiting blood, black or tarry stools, persistent abdominal pain, or symptoms in patients over 55 with new-onset reflux warrant urgent in-person investigation to exclude serious conditions such as oesophageal or stomach cancer.
Jste připraveni začít?
Vyplňte důvěrné zdravotní hodnocení za přibližně 3 minuty.